Dr Julie Cherrington Joins Xenome Ltd Board
8/11/2009 12:07:26 PM
Brisbane, Australia. 11 August 2009: Xenome Limited (“Xenome”) today announced that Dr
Julie Cherrington has joined the Xenome Board as an independent, Non-Executive Director.
Dr Cherrington is President of Phenomix Corporation, a San Diego based biopharmaceutical
company focused on the development and commercialisation of drugs for the treatment of
metabolic and infectious diseases. Prior to her appointment as President, Dr Cherrington
served as the Executive Vice President of Research and Development at Phenomix. Before
joining Phenomix, Dr Cherrrington held senior research positions at prominent biotechnology
companies such as SUGEN, Inc. and Gilead Sciences, Inc.
Recently Dr Cherrington joined the Board of ASX and NASDAQ listed Progen
Pharmaceuticals Limited. She has also served on the Board of ChemGenex Pharmaceuticals
Xenome’s Chairman, Mr Jim Hazel, welcomed Dr Cherrington’s appointment as an important
step in the ongoing evolution of the Xenome Board. “We are delighted to have a person of
Julie’s stature and experience join the Board and look forward to her help in building Xenome
as a drug development company.”
Dr Cherrington’s appointment took effect on 1 August 2009.
Xenome is a biotechnology company focused on the discovery and development of peptidebased
therapeutics. Utilising its expertise in peptide chemistry and its novel
technology platform, Xenome translates the evolutionary advantages inherent in venom
peptides into new drug candidates.
The Company's lead product, Xen2174, is a novel conopeptide analogue for the treatment
of moderate to severe pain. Xen2174 is a non-competitive inhibitor of
norepinephrine transporter (NET), a validated target for the management of pain. In an
international phase I/II clinical trial in cancer patients, a single intrathecal administration of
Xen2174 was found to be safe and well-tolerated across a broad dose range. In addition, the
study provided evidence for an analgesic effect that had a rapid onset of action and was longlasting.
Xenome's discovery platform is based on proprietary libraries of venom peptides,
analogues and mimetics. Research license agreements are in place with Amylin
Pharmaceuticals, Inc. (NASDAQ:AMLN) and MedImmune LLC (a wholly-owned subsidiary of
AstraZeneca), each of which have access to Xenome’s xdiscoverTM library for specific
indications or targets.
Further information can be obtained from the Xenome website (www.xenome.com).
comments powered by